Madrigal Pharmaceuticals, Inc. (MDGL)

Madrigal Pharmaceuticals Stock Forecast

Stock Price Forecast

The 11 analysts that cover Madrigal Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $674.45, which forecasts a 50.64% increase in the stock price over the next year. The lowest target is $529 and the highest is $964.

Price Target: $674.45 (+50.64%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$529	$674.45	$640	$964
Change	+18.15%	+50.64%	+42.95%	+115.31%

* Price targets were last updated on Feb 20, 2026.

Analyst Ratings

The average analyst rating for Madrigal Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Oct '25	Nov '25	Dec '25	Jan '26	Feb '26	Mar '26
Strong Buy	8	8	9	8	8	6
Buy	3	4	4	5	5	5
Hold	1	1	1	1	1	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	12	13	14	14	14	12

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Alexandria Hammond B of A Securities	B of A Securities	Hold Maintains $570 → $529	Hold	Maintains	$570 → $529	+18.15%	Feb 20, 2026
Eliana Merle Barclays	Barclays	Buy Initiates $964	Buy	Initiates	$964	+115.31%	Jan 28, 2026
Jonathan Wolleben Citizens	Citizens	Buy Maintains $527 → $745	Buy	Maintains	$527 → $745	+66.40%	Jan 20, 2026
Yasmeen Rahimi Piper Sandler	Piper Sandler	Buy Maintains $540 → $900	Buy	Maintains	$540 → $900	+101.02%	Dec 19, 2025
William Woods B. Riley Securities	B. Riley Securities	Strong Buy Maintains $560 → $670	Strong Buy	Maintains	$560 → $670	+49.65%	Dec 11, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

1.52B

Increased by 58.28%

from 958.40M

Revenue Next Year

2.23B

Increased by 46.80%

from 1.52B

EPS This Year

-4.80

from -12.85

EPS Next Year

11.89

from -4.80

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	-	-	-	180.13M	958.40M	1.52B	2.23B
Revenue Growth	-	-	-	-	432.05%	58.28%	46.80%
EPS	-14.63	-17.23	-19.99	-21.90	-12.85	-4.80	11.89
EPS Growth	-	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-	37.65
No. Analysts	-	-	-	-	-	18	17

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2026	2027	2028	2029	2030
High	1.7B	2.8B
Avg	1.5B	2.2B
Low	1.4B	1.7B

Revenue Growth

Revenue Growth	2026	2027	2028	2029	2030
High	76.2%	83.5%
Avg	58.3%	46.8%
Low	44.8%	8.8%

EPS Forecast

EPS	2026	2027	2028	2029	2030
High	2.26	20.11
Avg	-4.80	11.89
Low	-9.51	2.41

EPS Growth

EPS Growth	2026	2027	2028	2029	2030
High	-	-
Avg	-	-
Low	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.